Cited 8 times in
Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2022-09-14T01:41:27Z | - |
dc.date.available | 2022-09-14T01:41:27Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190569 | - |
dc.description.abstract | Purpose: Residual cardiovascular risk reduction by fenofibrate in patients with high serum triglyceride (TG) levels despite previous statin monotherapy is not well characterized. The purpose of this study was to evaluate the efficacy and safety of a combination of choline fenofibrate and statin in patients with inadequately controlled TG levels despite previous statin monotherapy. Methods: This prospective, multicenter, randomized, double-blind study was conducted in Korea. A total of 133 patients with controlled LDL-C but elevated TG levels, already receiving statin monotherapy, were enrolled in the study, which was conducted from July 2018 to December 2019. Patients were randomly assigned to receive combination therapy with choline fenofibrate and statin or statin monotherapy in a 1:1 ratio. After 8 weeks of treatment, the lipid profiles and safety parameters of the patients in the 2 groups were compared. Findings: The study included 127 patients (64 in the combination group and 63 in the control group) older than 19 years. After 8 weeks of therapy, mean serum TG levels significantly decreased from 269.8 to 145.5 mg/dL (P < 0.0001) in the combination therapy group, whereas no significant changes occurred in the statin monotherapy group (from 271.1 to 280.5 mg/dL). Contrarily, the mean serum HDLC levels significantly increased from 45.0 to 50.4 mg/dL (P = 0.0004) in the combination therapy group, whereas there were no significant changes in the monotherapy group (from 44.3 to 44.7 mg/dL). There were no additional serious adverse events in the combination therapy group compared with the statin monotherapy group. Implications: The combination therapy using choline fenofibrate and statin was found to be effective in serum TG control and likely tolerable in patients with high TG levels despite statin monotherapy. A larger study, conducted for a longer duration, is needed to evaluate the effectiveness of this combination in reducing cardiovascular risk. ClinicalTrials.gov identifier: NCT03874260. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Excerpta Medica | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Fenofibrate* / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects | - |
dc.subject.MESH | Hypolipidemic Agents / adverse effects | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Triglycerides | - |
dc.title | Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Myung Soo Park | - |
dc.contributor.googleauthor | Jong-Chan Youn | - |
dc.contributor.googleauthor | Eung Ju Kim | - |
dc.contributor.googleauthor | Ki Hoon Han | - |
dc.contributor.googleauthor | Sang Hak Lee | - |
dc.contributor.googleauthor | Sung Hea Kim | - |
dc.contributor.googleauthor | Byung Jin Kim | - |
dc.contributor.googleauthor | Sung Uk Kwon | - |
dc.contributor.googleauthor | Kyu-Hyung Ryu | - |
dc.identifier.doi | 10.1016/j.clinthera.2021.08.005 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J00614 | - |
dc.identifier.eissn | 1879-114X | - |
dc.identifier.pmid | 34518033 | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | Phase IV | - |
dc.subject.keyword | fenofibrate | - |
dc.subject.keyword | hyperlipidemia | - |
dc.subject.keyword | statin | - |
dc.subject.keyword | triglyceride | - |
dc.contributor.alternativeName | Lee, Snag Hak | - |
dc.contributor.affiliatedAuthor | 이상학 | - |
dc.citation.volume | 43 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1735 | - |
dc.citation.endPage | 1747 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, Vol.43(10) : 1735-1747, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.